Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease

Reimann, M.J.; Ljungvall, Ingrid; Hillström, Anna; Møller, Jacob Eifer; Hagman, Ragnvi; Falk, Torkel; Höglund, Katja; Häggström, Jens; Olsen, Lisbeth H.

doi:10.1016/j.tvjl.2015.12.006

Cited by 28 publications

(54 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our ndings of a positive correlation between CRP levels and LV diameter and LA/Ao ratio are in agreement with a previous report made in dogs with CHF (6). This nding and the negative correlation found between these cardiac variables and serum PON1 levels would indicate that APPs have possible role in the pathophysiology of CHF in dogs.…”

Section: Discussionsupporting

confidence: 93%

“…Although both of them are commonly considered non-in ammatory conditions (6,7), studies have found increased circulating in ammatory cytokines in dogs and humans with CHF due to MMVD (8,9) and DCM (7,10). Increased expression and release of in ammatory cytokines such as tumour necrosis factor (TNF-α), as well as serum C-reactive protein (CRP), have been described in humans (11,12) and dogs with CHF (13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure

Rubio

Sarıl

Kocatürk

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Heart failure (HF) has been associated with changes in inflammatory and oxidative-stress biomarkers. This study aimed to evaluate the changes of a panel of inflammatory and oxidative stress biomarker in dogs with different stages of HF and its relation with the severity of the disease and the echocardiographic changes. Dogs with HF as a result of myxomatous mitral valve degeneration or dilated cardiomyopathy were included. A total of 29 dogs were classified as stage-A (healthy), B (asymptomatic dogs), C (symptomatic dogs) and D (dogs with end-stage-HF) according to the ACVIM-staging-system. Serum cytokines, and inflammatory and oxidative stress markers were evaluated.Results: KC-like as an inflammatory cytokine was significantly increased in dogs of stage-C (P<0.01) and -D (P<0.05) compared with stage-A and -B. Stage-D Dogs showed significantly higher serum CRP and Hp (P<0.05) but lower serum anti-oxidant capacity (PON1, TEAC, CUPRAC, and thiol) compared to stage-A and -B (P<0.05). After the treatment, serum levels of CRP, Hp and KC-like decreased but serum anti-oxidant levels increased compared to their pre-treatment values. Left ventricular dimension and LA/Ao ratio correlated positively with CRP, MCP-1, and KC-like but negatively with PON1, GM-CSF, IL-7 and antioxidant biomarkers (P<0.01). Conclusion: our results indicated that dogs with advanced-stages of HF show increases in positive acute-phase proteins and selected inflammatory cytokines (KC-like), and decreases in antioxidant biomarkers, indicating that inflammation and oxidative-stress act as collaborative partners in the pathogenesis of HF. Some of these biomarkers of inflammation and oxidative stress could be tested as new biomarkers to monitor the severity of the disease and the effect of treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure

Rubio

Sarıl

Kocatürk

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The most commonly studied APP in heart failure is CRP. In dogs, CRP has been shown to be increased in CHF and correlated with disease severity 33,36,38 . It does not appear to be a major APP in cats, 64 but interestingly, we identified significant positive correlations of CRP with renal markers.…”

Section: Discussionmentioning

confidence: 57%

Cardiovascular‐renal axis disorder and acute‐phase proteins in cats with congestive heart failure caused by primary cardiomyopathy

Liu

Köster

Fosgate

et al. 2020

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Currently, the pathogenesis of congestive heart failure (CHF) in cats is not fully understood.Objective: To identify novel biomarkers for CHF in cats caused by primary cardiomyopathy, particularly related to cardiovascular-renal axis disorder and systemic inflammatory response.Animals: Twenty-five cats in CHF caused by primary cardiomyopathy, 12 cats with preclinical cardiomyopathy, and 20 healthy controls.Methods: Case control and observational case series. The following serum biomarkers were compared among the 3 cat groups: a cardiorenal profile that included N-terminal pro-brain natriuretic peptide (NT-proBNP), symmetric dimethylarginine (SDMA), and creatinine and an inflammatory profile that included 7 acute-phase proteins (APPs).Survival analyses and longitudinal studies were performed in CHF cats.Results: All cardiorenal biomarkers were positively correlated and higher in CHF cats, and high NT-proBNP and SDMA were associated with poor clinical outcome. Cats with CHF had significantly higher leucine-rich alpha-2-glycoprotein 1, serum amyloid A, and International Small Animal Cardiac Health Council; IVSd, interventricular septum thickness at end diastole; LA, left atrial; LA/Ao, left atrial-to-aortic root ratio; LRG1, leucine-rich alpha-2-glycoprotein 1; LV FS, left ventricular fractional shortening; LVFWd, left ventricular free wall thickness at end diastole; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCT, procalcitonin; PE, point estimate; RCM, restrictive cardiomyopathy; ROC, receiver operating characteristic; SAA, serum amyloid A; SDMA, symmetric dimethylarginine; SEC, spontaneous echocardiographic contrast; SPARCL, spatial proximity analyte reagent capture luminescence; UCM, unclassified cardiomyopathy.

show abstract

“…C‐reactive protein is a positive type II acute phase protein expressed in the liver69 in response to infection, inflammation, or cancer,70 and the serum CRP concentration is a nonspecific marker of inflammation 71, 72, 73, 74, 75, 76, 77, 78, 79, 80. Quantification of canine CRP in serum can be done using several assay formats,81, 82, 83, 84, 85, 86, 87, 88 all of which have a reference interval of approximately 0–8 mg/L.…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

108

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIE) in dogs are a group of disorders that are characterized by chronic persistent or recurrent signs of gastrointestinal disease and histologic evidence of mucosal inflammation. These CIEs are classified as either food‐responsive, antibiotic‐responsive, or immunosuppressant‐responsive enteropathy. Patients not clinically responding to immunomodulatory treatment are grouped as nonresponsive enteropathy and dogs with intestinal protein loss as protein‐losing enteropathy. Disease‐independent clinical scoring systems were established in dogs for assessment of clinical disease severity and patient monitoring during treatment. Histopathologic and routine clinicopathologic findings are usually not able to distinguish the subgroups of CIE. Treatment trials are often lengthy and further diagnostic tests are usually at least minimally invasive. Biomarkers that can aid in defining the presence of disease, site of origin, severity of the disease process, response to treatment, or a combination of these would be clinically useful in dogs with CIE. This article summarizes the following biomarkers that have been evaluated in dogs with CIE during the last decade, and critically evaluates their potential clinical utility in dogs with CIE: functional biomarkers (cobalamin, methylmalonic acid, folate, α1‐proteinase inhibitor, immunoglobulin A), biochemical biomarkers (C‐reactive protein, perinuclear anti‐neutrophilic cytoplasmic antibodies, 3‐bromotyrosine, N‐methylhistamine, calprotectin, S100A12, soluble receptor of advanced glycation end products, cytokines and chemokines, alkaline phosphatase), microbiomic biomarkers (microbiome changes, dysbiosis index), metabolomic biomarkers (serum metabolome), genetic biomarkers (genomic markers, gene expression changes), and cellular biomarkers (regulatory T cells). In addition, important performance criteria of diagnostic tests are briefly reviewed.

show abstract

Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease

Cited by 28 publications

References 43 publications

Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure

Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure

Cardiovascular‐renal axis disorder and acute‐phase proteins in cats with congestive heart failure caused by primary cardiomyopathy

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Contact Info

Product

Resources

About